Nxera Pharma Co., Ltd. launches a new pipeline focusing on next-generation therapies for obesity and metabolic disorders. This pipeline includes a proprietary oral small molecule GLP-1 agonist and six other innovative programs targeting various receptors. Nxera aims to address areas of patient need such as long-term weight management and co-morbid metabolic disorders. The company’s focused approach leverages its NxWave™ GPCR-focused design platform to identify unique lead molecules with novel chemistry. Nxera aims to deliver effective therapies for long-term weight maintenance and obesity-related co-morbidities. Additionally, Nxera maintains a commitment to other therapeutic areas like neurology and immunology.

Read more at GlobeNewswire: Nxera Launches Broad Proprietary Pipeline Targeting Obesity